Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.

Pae CU, Jeon HJ, Lee BC, Seo HJ, Kim SG, Park EJ, Kim W, Kwak KP, Han C, Cho SJ, Hahn SW, Jon DI, Choi JH, Jun TY.

Int Clin Psychopharmacol. 2013 Nov;28(6):322-9. doi: 10.1097/YIC.0b013e3283643728.

PMID:
23873293
2.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
3.

Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.

Jon DI, Kim DH, Seo HJ, Kwon YJ, Kim MD, Yang JC, Suh HS, Min KJ, Pae CU, Bahk WM.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):157-61. doi: 10.1097/WNF.0b013e3182a31f3d.

PMID:
24045606
5.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
6.

Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).

Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T; ADMIRE Study Group.

J Affect Disord. 2013 Dec;151(3):899-905. doi: 10.1016/j.jad.2013.07.035. Epub 2013 Aug 28.

7.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
8.

The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.

Chen SJ, Hsiao YL, Shen TW, Chen ST.

J Clin Psychopharmacol. 2012 Feb;32(1):56-60. doi: 10.1097/JCP.0b013e31823f6c7f.

PMID:
22198444
9.

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.

J Clin Psychiatry. 2008 Dec;69(12):1928-36. Epub 2008 Dec 2.

PMID:
19192475
10.

Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.

Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC.

J Affect Disord. 2014 Jun;162:20-5. doi: 10.1016/j.jad.2014.03.017. Epub 2014 Mar 24.

11.

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012;81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.

PMID:
22286203
12.

A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.

Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN.

J Affect Disord. 2008 Sep;110(1-2):70-4. doi: 10.1016/j.jad.2008.01.004. Epub 2008 Feb 12.

PMID:
18272230
13.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
14.

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.

Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN.

Curr Med Res Opin. 2010 Jun;26(6):1485-96. doi: 10.1185/03007991003779380.

PMID:
20429835
15.

Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.

Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P.

Expert Opin Pharmacother. 2008 Dec;9(18):3145-9. doi: 10.1517/14656560802504490 .

PMID:
19040335
16.

Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.

Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS.

Int Clin Psychopharmacol. 2014 Mar;29(2):116-9. doi: 10.1097/YIC.0000000000000012.

PMID:
24108149
17.

Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.

Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH.

Depress Anxiety. 2007;24(7):522-6.

PMID:
17111388
18.

Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.

Han C, Wang SM, Kwak KP, Won WY, Lee H, Chang CM, Tang TC, Pae CU.

J Psychiatr Res. 2015 Jul-Aug;66-67:84-94. doi: 10.1016/j.jpsychires.2015.04.020. Epub 2015 May 5.

PMID:
26013203
19.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.

J Clin Psychiatry. 2011 Apr;72(4):548-55. doi: 10.4088/JCP.09m05495gre. Epub 2010 Aug 24.

PMID:
20816039
20.

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM.

J Clin Psychopharmacol. 2009 Aug;29(4):362-7. doi: 10.1097/JCP.0b013e3181ac9b0b.

PMID:
19593176

Supplemental Content

Support Center